|
|
Profile
|
Delegates :
Hideaki Ogasawara |
|
Incorporated :
September 13 , 2018 |
Paid in Capital :
5 Million yen |
Employees :
2 人 |
Address :
#403, Todaimae HiRAKU GATE 2-3-10, Mukogaoka, Bunkyo City TOKYO
〒1130023
|
TEL/FAX :
+81 3 3868 2260‬ / |
URL：
https://www.tansobio.com/ |
Attachment :
 leaflet_tanso_en.pdf [ 842.9KiB ] |
Mission/Background :
Researchers at the University of Tokyo invented a highly sensitive, comprehensive cell-based GPCR assay. Tanso Biosciences was founded in 2018 to commercialize it, patented in Japan (2023) and the US (2025; WO/2020/026979).
Our business has two pillars: contract screening of 550 human/mouse GPCRs, including hard-to-assay orphan, G12/13-, and Gi/o-coupled receptors, and in-house drug discovery. Since 2020, we have served repeat pharma, biotech, food, and academic clients in Japan, the US, and Europe. |
|
Technology & Business
|
Founded in 2018, Tanso Biosciences began offering contract assay services in 2020. Since then, we have served clients in Japan, the US, and Europe, including pharma companies, biotech ventures, food companies, universities, and public research institutes, maintaining stable revenue and a high repeat rate.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Comprehensive functional assay for 550 human and mouse GPCRs
|
Service/Marketing
|
We provide highly sensitive, comprehensive GPCR functional assays covering 550 human/mouse receptors in flexible formats.
|
To develop partnership with pharmaceuticals and biotechs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Founded in 2018, Tanso Biosciences began offering contract assay services in 2020. Since then, we have served clients in Japan, the US, and Europe, including pharma companies, biotech ventures, food companies, universities, and public research institutes, maintaining stable revenue and a high repeat rate. Our core technology was filed as an international patent by The University of Tokyo in 2019, under which Tanso holds an exclusive license; the patent was registered in Japan in 2023 and the US in 2025.
|
|
Hot news
|
International patent filed in July, 2019. Negotiation under NDA ongoing with several pharmaceuticals and biotechs.
|
|
Alliance strategy
|
We conduct GPCR functional assays on a contract basis. We also seek opportunities to collaborate with pharmaceuticals and biotechs in drug research.
|
|
|